Omnigen is a team of ambitious scientists who all have a background in genetics and/or bio-informatics. Omnigen tries to find the answers to medical, genetic and biological questions from different fields with the help of the latest scientific and technical findings.
Omnigen is aiming to use biological knowledge and research in a positive and useful way for society. We do this by, for example, bring the results of scientific research closer to the broad public. We also develop methods to make the treatment of illnesses better and more efficient and we do research to accelerate and professionalize the development of partners.
The group of Omnigen BV is characterized by different operating companies who each have their own different theme or focus point but are bundled together in the parent company Omnigen.
Omnigen has the goal to exploit Personalised Medicine, Clinical Diagnostics and innovative (biological) research, in a way that has a positive influence on society and on the public health. They do this by using their knowledge and expertise for medical and scientific research, for services for the farmaceutical industry, and the development of (computational) methods for better treatments of illnesses for patients.
DNAisYou is aiming to market Direct To Consumer (DTC) testing in a creative way to ensure that the broader public can get to know the results of scientific research in a playful, easy to understand and informative way. The underlying goal is to enable people to live a healthier lifestyle by having biological self-awareness.
Anigen applies the acquired knowledge and expertise of Omnigen to services and products for pets/animals. They do this by developing new biological tests but also by independent genetic research. The goal is to exploit this on, for example, the para-veterinary market and the animal-oriented research departments of universities. Anigen does this to improve the lives of pets/animals and to improve the professional breeding of pets/animals.
Praedico is aiming to develop pharmaceutical compounds to make the production of medication more efficient. This will help to bring medication to the market and patients faster and cheaper. Also has Preadico an IP and patent that has the potential to identify tumors that are not or not easy to identify, in a non-invasive manner. This way, patients will be able to get treated in a more efficient and in an individual (tumor-specific) way.